Mitoxantrone 2mg/mL
        
            
            
                | Product Overview | 
                        | Generic Name | Mitoxantrone 2mg/mL | 
                                    | Brand Name(s) | Novantrone (original), Sun’s Oncotron, VHB’s Mitozan (India) | 
                                    | Form | Intravenous solution; lyophilized powder for injection (vial) | 
                                    | Strength | 2mg/mL | 
                                    | Therapeutic Class | Anthracenedione antitumor antibiotic | 
                                    | ATC Code | L01BA04 | 
            
            
            
                | Manufacturing & Regulatory | 
                        | Manufacturer | Roche (originator); Indian suppliers: Ocean Pharma, Saintroy Lifescience, Lexicare, PBP Enterprises | 
                                    | Country | India, USA | 
                                    | GMP Compliance | ISO, cGMP, WHO-GMP | 
                                    | DMF/CEP | Indian generics hold Type II | 
                                    | COFEPRIS | Registered (product available for import) | 
                                    | Free Sale Certificate | Yes | 
            
            
            
                | Logistics & Export | 
                        | MOQ | 20 vials | 
                                    | Shelf Life | 24 Months | 
                                    | Storage | refrigerated at 2–8 °C | 
                                    | Incoterms | FOB / CIF / DDP standard | 
                                    | Lead Time | 7 to 10 Days | 
            
            
            
                | Documentation | 
                        | Certificate of Analysis (COA) | Provided by manufacturer/distributor | 
                                    | SDS | Cytotoxic infusion handling sheet; MSDS available from manufacturer when requested | 
                                    | CTD Summary | CTD dossier available upon request from supplier | 
            
        
                    
                
Description
                Indications & Usage): Short-form: Approved for acute nonlymphocytic leukemia, metastatic breast cancer, advanced prostate cancer, and secondary progressive multiple sclerosis            
        
       
            Request for Quote